Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Exelixis Releases Updated Phase 2 Data

By Drug Discovery Trends Editor | June 8, 2011

Exelixis, Inc. reported updated interim data from a fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

The data provide additional patient experience and longer-term follow-up showing that cabozantinib results in resolution or stabilization of metastatic bone lesions on bone scan in the majority of patients evaluable by this method.

Cabozantinib treatment relieved or eliminated bone pain in the majority of patients, thus allowing for most who require narcotic analgesic medication to either reduce or eliminate the use of these medicines. Patients with partial or complete resolution of metastatic bone lesions by bone scan were more likely to remain free of disease progression after six months, experience pain relief, reduce or eliminate their use of narcotic analgesics, achieve tumor regression, and experience marked declines in markers of bone turnover when compared to those who did not achieve bone scan resolution.

Updated progression-free survival (PFS) data show that cabozantinib results in median PFS that appears to be similar in docetaxel-naïve and pretreated patients, and compares favorably to population matched historical controls. In the randomized discontinuation phase of the study, significant improvement in median PFS was observed in patients randomized to cabozantinib. Despite only 31 patients randomized at week 12, the results were highly statistically significant, suggestive of a sizable treatment effect over placebo. Durable increases in hemoglobin levels in anemic patients were also observed.

All 171 patients enrolled in the trial had measurable soft tissue disease per mRECIST, of which 37% had evidence of disease in liver or lung. The bone scan evaluable population includes 108 patients with evidence of bone metastasis, a baseline bone scan, and at least 1 post-baseline bone scan assessment. Prior therapies included docetaxel, abiraterone/MDV3100, and other cytotoxic and/or experimental agents.

In the randomized discontinuation phase, a total of 31 patients with stable disease (SD) at week 12 were randomized to either placebo or cabozantinib. From week 12 onward, the investigator-assessed median PFS is 6 weeks for the placebo group, and 21 weeks (for the cabozantinib group. The hazard ratio strongly favored the cabozantinib arm and corresponds to an 87% reduction in the risk of progression for patients treated with cabozantinib compared with placebo.

Release Date: June 6, 2011
Source: Exelixis, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50